AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home iLABMED Article
PDF (551.6 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Biomarkers for predicting efficacy of chimeric antigen receptor T cell therapy and their detection methods

Bo Zou1,2, Yanzhou Song3, Ning Li1, Zhongyi Fan1, Jie Li4, Yuanzheng Peng5,6, Wanshan Wei1, Yuzi Zhang7, Yinan Su3, Xianmin Meng8, Hongzhou Lu4( ), Xingding Zhang2( ), Xiaohua Tan1( ), Qibin Liao1 ( )
Department of Oncology and Bio‐Therapeutic Center, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China
Molecular Cancer Research Center, School of Medicine, Shenzhen Campus of Sun Yat‐Sen University, Sun Yat‐Sen University, Shenzhen, China
Department of Hepato‐Biliary Surgery, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China
Institute for Hepatology, National Clinical Research Centre for Infectious Diseases, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China
Kidney Transplant Department (Liver Transplant Department), Transplant Center, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China
Institute of Translational Medicine, First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong China
BASIS International School, Huizhou, Guangdong China
Department of Pharmacy, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China

Bo Zou, Yanzhou Song and Ning Li contributed equally.

Show Author Information

Graphical Abstract

This review provides a comprehensive overview of the factors predicting the efficacy of chimeric antigen receptor T (CAR‐T) cell therapy, with a particular focus on biomarkers and their detection methods. Six key factors were potential predictors for the efficacy of CAR‐T cell therapy: (1) age, (2) tumor burden, (3) cytokines, (4) cell subtypes, (5) antigen density, and (6) tumor microenvironment.

Abstract

Cancer immunotherapy has emerged as the fourth most prevalent approach to tumor treatment, alongside surgery, radiotherapy, and chemotherapy. After several decades of development, chimeric antigen receptor T (CAR‐T) cell therapy, a promising branch of adoptive T‐cell therapy, has demonstrated superior efficacy and safety in comparison to other cell therapies in the treatment of cancer. At present, CAR‐T cells are predominantly used to treat hematological malignancies, although their application in solid tumors is being readily investigated. Although numerous studies have examined the biomarkers associated with the safety of CAR‐T cell therapy, few have evaluated predictors of CAR‐T cell therapeutic efficacy. Thus, the primary objective of this review article was to provide a comprehensive overview of the factors predicting the efficacy of CAR‐T cell therapy, with a particular focus on biomarkers and their detection methods.

Keywords

biomarkerscancer immunotherapyCAR‐T celldetection methodstherapeutic efficacy

References

[1]

Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994;64(3):529–64. https://doi.org/10.1016/0163-7258(94)90023-X
Crossref Google Scholar
[2]

McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft‐tissue sarcomas. Iowa Orthop J. 2006;26:154–8.
Google Scholar
[3]

Li L, Xie CY, Zheng MY, Jiang HL. Advances in research on tumor immunotherapy. Chin J Nature. 2021;43(6):391–9. https://www.nature.shu.edu.cn/CN/10.3969/j.issn.0253-9608.2021.06.001
Crossref Google Scholar
[4]

Filin IY, Solovyeva VV, Kitaeva KV, Rutland CS, Rizvanov AA. Current trends in cancer immunotherapy. Biomedicines. 2020;8(12):621. https://doi.org/10.3390/biomedicines8120621
Crossref Google Scholar
[5]

Tang J, Pearce L, O'Donnell‐Tormey J, Hubbard‐Lucey VM. Trends in the global immuno‐oncology landscape. Nat Rev Drug Discov. 2018;17(11):783–4. https://doi.org/10.1038/nrd.2018.167
Crossref Google Scholar
[6]

Saez‐Ibañez AR, Upadhaya S, Partridge T, Shah M, Correa D, Campbell J. Landscape of cancer cell therapies: trends and real‐world data. Nat Rev Drug Discov. 2022;21(9):631–2. https://doi.org/10.1038/d41573-022-00095-1
Crossref Google Scholar
[7]

Srivastava S, Riddell SR. Engineering CAR‐T cells: design concepts. Trends Immunol. 2015;36(8):494–502. https://doi.org/10.1016/j.it.2015.06.004
Crossref Google Scholar
[8]

Lu J, Jiang G. The journey of CAR‐T therapy in hematological malignancies. Mol Cancer. 2022;21(1):194. https://doi.org/10.1186/s12943-022-01663-0
Crossref Google Scholar
[9]

Hay KA, Turtle CJ. Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B‐cell malignancies. Drugs. 2017;77(3):237–45. https://doi.org/10.1007/s40265-017-0690-8
Crossref Google Scholar
[10]

Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30‐expressing cells and lymphoma cell lines. Blood. 1994;83(8):2045–56. https://doi.org/10.1182/blood.v83.8.2045.2045
Crossref Google Scholar
[11]

Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33‐targeted immunotherapy. Blood. 2012;119(26):6198–208. https://doi.org/10.1182/blood-2011-11-325050
Crossref Google Scholar
[12]

Sun C, Mahendravada A, Ballard B, Kale B, Ramos C, West J, et al. Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. Oncotarget. 2019;10(24):2369–83. https://doi.org/10.18632/oncotarget.26792
Crossref Google Scholar
[13]

Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA‐based immunotherapy. Front Immunol. 2018;9:1821. https://doi.org/10.3389/fimmu.2018.01821
Crossref Google Scholar
[14]

Yang YH, Liu JW, Lu C, Wei JF. CAR‐T cell therapy for breast cancer: from basic research to clinical application. Int J Biol Sci. 2022;18(6):2609–26. https://doi.org/10.7150/ijbs.70120
Crossref Google Scholar
[15]

Hu Z, Zheng X, Jiao D, Zhou Y, Sun R, Wang B, et al. LunX‐CAR T cells as a targeted therapy for non‐small cell lung cancer. Mol Ther Oncolytics. 2020;17:361–70. https://doi.org/10.1016/j.omto.2020.04.008
Crossref Google Scholar
[16]

Kim TJ, Lee YH, Koo KC. Current and future perspectives on CAR‐T cell therapy for renal cell carcinoma: a comprehensive review. Investig Clin Urol. 2022;63(5):486–98. https://doi.org/10.4111/icu.20220103
Crossref Google Scholar
[17]

Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G, et al. Claudin18.2‐specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019;111(4):409–18. https://doi.org/10.1093/jnci/djy134
Crossref Google Scholar
[18]

Han D, Xu Z, Zhuang Y, Ye Z, Qian QQ. Current progress in CAR‐T cell therapy for hematological malignancies. J Cancer. 2021;12(2):326–34. https://doi.org/10.7150/jca.48976
Crossref Google Scholar
[19]

Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321–30. https://doi.org/10.1182/blood-2016-04-703751
Crossref Google Scholar
[20]

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026
Crossref Google Scholar
[21]

Ahmadzadehfar H, Rodrigues M, Zakavi R, Knoll P, Mirzaei S. Prognostic significance of the standardized uptake value of pre‐therapeutic (18)F‐FDG PET in patients with malignant lymphoma. Med Oncol. 2011;28(4):1570–6. https://doi.org/10.1007/s12032-010-9584-2
Crossref Google Scholar
[22]

Stadler JC, Belloum Y, Deitert B, Sementsov M, Heidrich I, Gebhardt C, et al. Current and future clinical applications of ctDNA in immuno‐oncology. Cancer Res. 2022;82(3):349–58. https://doi.org/10.1158/0008-5472.CAN-21-1718
Crossref Google Scholar
[23]

Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15(1):131. https://doi.org/10.1186/s13045-022-01351-y
Crossref Google Scholar
[24]
Tuo X, Cheng J, Liu CX. Study on enzymatic kinetic characterizations of the immobilized lactate dehydrogenase in reversed micelles. J Anal Sci. 2008;03:280–282. http://fxkx.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=70211027-bf26-435d-9042-11658a19d95e
[25]

Hu L, Chen X, Chen M, Fang J, Nie J, Dai H. Enrichment and detection of circulating tumor cells by immunomagnetic beads and flow cytometry. Biotechnol Lett. 2021;43(1):25–34. https://doi.org/10.1007/s10529-020-03007-8
Crossref Google Scholar
[26]

Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, Xu Y. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol. 2011;137(8):1151–73. https://doi.org/10.1007/s00432-011-0988-y
Crossref Google Scholar
[27]

Huang RP. Cytokine protein arrays. Methods Mol Biol. 2004;264:215–31. https://doi.org/10.1385/1-59259-759-9:215
Crossref Google Scholar
[28]

Merkel PA, Lebo T, Knight V. Functional analysis of anti‐cytokine autoantibodies using flow cytometry. Front Immunol. 2019;10:1517. https://doi.org/10.3389/fimmu.2019.01517
Crossref Google Scholar
[29]

Morgan E, Varro R, Sepulveda H, Ember JA, Apgar J, Wilson J, et al. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol. 2004;110(3):252–66. https://doi.org/10.1016/j.clim.2003.11.017
Crossref Google Scholar
[30]

Maier R, Weger M, Haller‐Schober EM, El‐Shabrawi Y, Theisl A, Barth A, et al. Application of multiplex cytometric bead array technology for the measurement of angiogenic factors in the vitreous. Mol Vis. 2006;12:1143–7.
Google Scholar
[31]

van Maarsseveen TC, Mullink H, de Haan M, de Groot J, Stam J, Meijer CJ. Simultaneous enumeration of T‐cell subsets and macrophages in bronchoalveolar lavage fluids by immunoenzyme double staining. Comparison with conventional immunofluorescence. Acta Cytol. 1989;33(4):550–6.
Google Scholar
[32]

McKinnon KM. Flow cytometry: an overview. Curr Protoc Immunol. 2018;120:5.1.1–5.1.11. https://doi.org/10.1002/cpim.40
Crossref Google Scholar
[33]

Naour FL. Identification of tumor antigens by using proteomics. Methods Mol Biol. 2007;360:327–34. https://doi.org/10.1385/1-59745-165-7:327
Crossref Google Scholar
[34]

Lee YM, Jeong Y, Kang HJ, Chung SJ, Chung BH. Cascade enzyme‐linked immunosorbent assay (CELISA). Biosens Bioelectron. 2009;25(2):332–7. https://doi.org/10.1016/j.bios.2009.07.010
Crossref Google Scholar
[35]

Yu X, Li P, Wang AA, Feng H, Yin Z, Li Y, et al. Quick identification of target antigens by tissue flow cytometry for CAR‐T therapy in B‐cell malignancies. Cytometry B Clin Cytom. 2022;102(4):317–9. https://doi.org/10.1002/cyto.b.22060
Crossref Google Scholar
[36]

Amereh M, Akbari M. Immunohistochemistry (IHC) staining of in‐vitro cancer cell‐generated tumoroids. MethodsX. 2023;10:102242. https://doi.org/10.1016/j.mex.2023.102242
Crossref Google Scholar
[37]

Tracey LJ, An Y, Justice MJ. CyTOF: an emerging technology for single‐cell proteomics in the mouse. Curr Protoc. 2021;1(4):e118. https://doi.org/10.1002/cpz1.118
Crossref Google Scholar
[38]

Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol. 2016;41:23–31. https://doi.org/10.1016/j.coi.2016.05.006
Crossref Google Scholar
[39]

Lee SE, Wang F, Ocampo AT, Vasquez WR, Cho HW, Takahashi K, et al. Fidelity of peripheral blood for monitoring genomics and tumor immune microenvironment in myelodysplastic syndromes. EJHaem. 2020;1(2):552–7. https://doi.org/10.1002/jha2.112
Crossref Google Scholar
[40]

Guha P, Cunetta M, Somasundar P, Espat NJ, Junghans RP, Katz SC. Frontline science: functionally impaired geriatric CAR‐T cells rescued by increased alpha 5 beta 1 integrin expression. J Leukoc Biol. 2017;102(2):201–8. https://doi.org/10.1189/jlb.5HI0716‐322RR
Crossref Google Scholar
[41]

Xu X, Sun Q, Liang X, Chen Z, Li Y, Zhang X, et al. Mechanisms of relapse after CD19 CAR T‐cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664. https://doi.org/10.3389/fimmu.2019.02664
Crossref Google Scholar
[42]

Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard‐of‐care axicabtagene ciloleucel for relapsed or refractory large B‐cell lymphoma: results from the US lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119–28. https://doi.org/10.1200/JCO.19.02104
Crossref Google Scholar
[43]

Locke FL, Rossi JM, Neelapu S, Jacobson CA, Miklos DB, Ghobadi A, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B‐cell lymphoma. Blood Adv. 2020;4(19):4898–911. https://doi.org/10.1182/bloodadvances.2020002394
Crossref Google Scholar
[44]

Ding J, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomarkers. 2017;19(4):353–63. https://doi.org/10.3233/CBM-160336
Crossref Google Scholar
[45]

Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B‐cell ALL patients achieving MRD‐negative CR after CD19 CAR T‐cell therapy. Blood. 2019;133(15):1652–63. https://doi.org/10.1182/blood-2018-11-883710
Crossref Google Scholar
[46]

Zhou X, Ge T, Li T, Huang L, Cao Y, Xiao Y, et al. CAR19/22 T cell therapy in adult refractory Burkitt's lymphoma. Cancer Immunol Immunother. 2021;70(8):2379–84. https://doi.org/10.1007/s00262-021-02850-6
Crossref Google Scholar
[47]

Vercellino L, Blasi RD, Kanoun S, Tessoulin B, Rossi C, Aveni‐Piney MD, et al. Predictive factors of early progression after CAR T‐cell therapy in relapsed/refractory diffuse large B‐cell lymphoma. Blood Adv. 2020;4(22):5607–15. https://doi.org/10.1182/bloodadvances.2020003001
Crossref Google Scholar
[48]

Jodon G, Colton MD, Abbott D, Cai A, Haverkos B, Morgan R, et al. Clinical and radiographic predictors of progression and survival in relapsed/refractory lymphoma patients receiving anti‐CD19 CAR T‐cell therapy. Clin Lymphoma Myeloma Leuk. 2023;23(1):49–56. https://doi.org/10.1016/j.clml.2022.09.009
Crossref Google Scholar
[49]

Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma remissions caused by anti‐CD19 chimeric antigen receptor T cells are associated with high serum interleukin‐15 levels. J Clin Oncol. 2017;35(16):1803–13. https://doi.org/10.1200/JCO.2016.71.3024
Crossref Google Scholar
[50]

Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Grupp SA, Maude SL, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T‐cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664–79. https://doi.org/10.1158/2159-8290.CD-16-0040
Crossref Google Scholar
[51]

Liu Y, Jie X, Nian L, Wang Y, Wang C, Ma J, et al. A combination of pre‐infusion serum ferritin, CRP and IL‐6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR‐T cells. Front Immunol. 2023;14:1169071. https://doi.org/10.3389/fimmu.2023.1169071
Crossref Google Scholar
[52]

Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade‐long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature. 2022;602(7897):503–9. https://doi.org/10.1038/s41586-021-04390-6
Crossref Google Scholar
[53]

Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, et al. Distinct cellular dynamics associated with response to CAR‐T therapy for refractory B cell lymphoma. Nat Med. 2022;28(9):1848–59. https://doi.org/10.1038/s41591-022-01959-0
Crossref Google Scholar
[54]

Pan Y, Wang H, An F, Wu F, Tao Q, Li Y, et al. CD4(+)CD25(+)CD127(low) regulatory T cells associated with the effect of CD19 CAR‐T therapy for relapsed/refractory B‐cell acute lymphoblastic leukemia. Int Immunopharmacol. 2021;96:107742. https://doi.org/10.1016/j.intimp.2021.107742
Crossref Google Scholar
[55]

Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019;20(6):1283. https://doi.org/10.3390/ijms20061283
Crossref Google Scholar
[56]

Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, et al. Mechanisms of relapse after CD19 CAR T‐cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664. https://doi.org/10.3389/fimmu.2019.02664
Crossref Google Scholar
[57]

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DB, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17. https://doi.org/10.1056/NEJMoa1407222
Crossref Google Scholar
[58]

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor‐modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18. https://doi.org/10.1056/NEJMoa1215134
Crossref Google Scholar
[59]

Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145–61. https://doi.org/10.1038/s41568-020-00323-z
Crossref Google Scholar
[60]

Zhang Z, Chen X, Tian Y, Li F, Zhao X, Liu J, et al. Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR‐T cell therapy. J Immunother Cancer. 2020;8(2):e001150. https://doi.org/10.1136/jitc-2020-001150
Crossref Google Scholar
[61]

Lemoine J, Ruella M, Houot R. Born to survive: how cancer cells resist CAR T cell therapy. J Hematol Oncol. 2021;14(1):199. https://doi.org/10.1186/s13045-021-01209-9
Crossref Google Scholar
[62]

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50. https://doi.org/10.1038/s41591-018-0014-x
Crossref Google Scholar
[63]

Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, et al. Tumor immune contexture is a determinant of anti‐CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med. 2022;28(9):1872–82. https://doi.org/10.1038/s41591-022-01916-x
Crossref Google Scholar
[64]

Palmer MK. WHO handbook for reporting results of cancer treatment. Br J Cancer. 1982;45:484–5. https://doi.org/10.1038/bjc.1982.83
Crossref Google Scholar
[65]

Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B‐cell lymphoma. Blood Adv. 2020;4(14):3268–76. https://doi.org/10.1182/bloodadvances.2020001900
Crossref Google Scholar
[66]

Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6(1):404. https://doi.org/10.1038/s41392-021-00817-8
Crossref Google Scholar
[67]

Wang W, Sun X, Jin W. Determination of lactate dehydrogenase in human erythrocytes by capillary electrophoresis with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;798(1):175–8. https://doi.org/10.1016/j.jchromb.2003.09.036
Crossref Google Scholar
[68]

Komoda T, Sakagishi Y, Mizushima H. Determination of isoenzyme contents of lactic dehydrogenase activity and 2‐hydroxybutyric dehydrogenase activity in lactic dehydrogenase preparations. Clin Chim Acta. 1976;72(3):285–93. https://doi.org/10.1016/0009-8981(76)90190-x
Crossref Google Scholar
[69]

Arabi F, Torabi‐Rahvar M, Shariati A, Ahmadbeigi N, Naderi M. Antigenic targets of CAR T cell therapy. A retrospective view on clinical trials. Exp Cell Res. 2018;369(1):1–10. https://doi.org/10.1016/j.yexcr.2018.05.009
Crossref Google Scholar
iLABMED
Volume 2 Issue 1,
March 2024
Pages 14-26
DOI: 10.1002/ila2.31
Cite this article:
Zou B, Song Y, Li N, et al. Biomarkers for predicting efficacy of chimeric antigen receptor T cell therapy and their detection methods. iLABMED, 2024, 2(1): 14-26. https://doi.org/10.1002/ila2.31

422

Views

35

Downloads

0

Crossref

Altmetrics
Received: 26 September 2023
Accepted: 08 January 2024
Published: 16 February 2024
© 2024 The Authors. Tsinghua University Press.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Return